Skip to content
10-Q

Quarterly Report

PURE Bioscience, Inc. PURE

0001493152-24-050227

← back to feed
Filed
Dec 16, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Dec 16, 2024 111.86M sh
Current Liabilities Q1 2025 · Oct 31, 2024 $911K
Current Liabilities Q1 2025 · Jul 31, 2024 $733K
Total Liabilities Q1 2025 · Oct 31, 2024 $4.42M
Total Liabilities Q1 2025 · Jul 31, 2024 $3.68M
Current Assets Q1 2025 · Oct 31, 2024 $911K
Current Assets Q1 2025 · Jul 31, 2024 $805K
Total Assets Q1 2025 · Oct 31, 2024 $924K
Total Assets Q1 2025 · Jul 31, 2024 $818K
Cash And Equivalents Q1 2025 · Jul 31, 2024 $349K
Cash And Equivalents Q1 2025 · Oct 31, 2023 $1.44M
Shares Diluted Q1 2025 · Oct 31, 2023 111.86M sh
Operating Cash Flow Q1 2025 · Oct 31, 2023 −$440K
Stockholders Equity Q1 2025 · Oct 31, 2023 −$383K
Stockholders Equity Q1 2025 · Jul 31, 2023 $272K
Eps Diluted Q1 2025 · Oct 31, 2023 −$0.01
Eps Basic Q1 2025 · Oct 31, 2023 −$0.01
Sga Expense Q1 2025 · Oct 31, 2023 $1.07M
Rd Expense Q1 2025 · Oct 31, 2023 $80K
Net Income Q1 2025 · Oct 31, 2023 −$735K
Operating Income Q1 2025 · Oct 31, 2023 −$711K
Gross Profit Q1 2025 · Oct 31, 2023 $442K
Cost Of Revenue Q1 2025 · Oct 31, 2023 $280K
Revenue Q1 2025 · Oct 31, 2023 $722K